🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Chemed CEO Kevin McNamara sells shares worth over $816k

Published 06/07/2024, 03:14 PM
CHE
-

Chemed Corp (NYSE:CHE) President and CEO Kevin J. McNamara has sold 1,500 shares of the company's stock, according to a recent SEC filing. The transaction, which took place on June 6, 2024, resulted in a total sale value of $816,254, with the shares sold at a weighted average price of $544.17 each.

The sale was conducted in multiple transactions at prices ranging from $541.94 to $548.00, as detailed in the footnotes of the SEC filing. Following the sale, McNamara still owns 107,049 shares of Chemed Corp, indicating a continued significant stake in the company he leads.

Chemed Corp, known for its healthcare services including hospice and palliative care, has been a subject of investor interest, and executive transactions are closely watched for indications of leadership confidence and market sentiment.

Investors and market analysts often monitor the buying and selling activities of company insiders such as CEOs for insights into a company's financial health and future prospects. The recent transaction by McNamara may be interpreted in various ways, but it remains a single data point in the broader context of Chemed Corp's operational performance and market activities.

The company has not made any official statement regarding the reasons behind McNamara's stock sale, and it is not uncommon for executives to sell shares for personal financial management reasons. Shareholders and potential investors are encouraged to consider the full spectrum of information available when evaluating their investment decisions related to Chemed Corp.

In other recent news, Chemed Corporation experienced a mixture of triumphs and trials. The company's VITAS Healthcare unit posted strong performance, with an optimistic outlook for patient census growth, boosted by the recent acquisition of Covenant Care. However, Chemed's Roto-Rooter business encountered headwinds, resulting in a 5.8% revenue decrease year-over-year in the first quarter. These contrasting performances led RBC Capital to adjust its price target for Chemed shares, despite maintaining an Outperform rating.

In other developments, Chemed shareholders elected a slate of 10 directors and ratified PricewaterhouseCoopers LLP as the company's independent accountants for 2024 during their recent annual meeting. They also approved the company's executive compensation but voted against a proposal concerning the ratification of termination pay. The Board of Directors declared a quarterly cash dividend of 40 cents per share, continuing Chemed's long-standing history of dividend payments. These are among the recent developments in the company's journey.

InvestingPro Insights

As Chemed Corp's leadership makes notable moves in the stock market, investors are keen to grasp the full financial picture of the company. With a market capitalization of $8.23 billion and a P/E ratio standing at 28.9, Chemed Corp presents a robust investment profile. The company's commitment to shareholder value is evident through its consistent dividend payments, having maintained them for an impressive 54 consecutive years—a testament to its financial stability and an attractive point for income-focused investors, as highlighted by InvestingPro Tips.

Despite recent volatility in the stock price, with a 1-month total return of -6.17% and a 3-month total return of -16.22%, Chemed Corp has demonstrated a solid track record of profitability over the last twelve months. The company's revenue growth remains positive, with a 5.96% increase in the last twelve months as of Q1 2024, indicating a steady upward trajectory. Additionally, Chemed's ability to generate a return on assets of 17.94% showcases efficient use of its assets to generate earnings.

For investors seeking a deeper dive into Chemed Corp's financial health and future prospects, InvestingPro Tips offer further guidance, such as the company's high P/E ratio relative to near-term earnings growth and its moderate level of debt. These insights, along with 11 additional tips available on InvestingPro, can provide valuable context to McNamara's recent stock sale and the company's overall investment potential. When subscribing to InvestingPro, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.